Literature DB >> 11481261

Involvement of Sp1 elements in the promoter activity of genes affected in keratoconus.

Y Maruyama1, X Wang, Y Li, J Sugar, B Y Yue.   

Abstract

PURPOSE: Keratoconus is a progressive disease that thins and scars the corneal stroma. In keratoconus corneas, levels of degradative enzymes, including lysosomal acid phosphatase (LAP) and cathepsin B, are elevated, and those of the inhibitors alpha1-proteinase inhibitor (alpha 1-PI) and alpha 2-macroglobulin (alpha 2-M) are reduced, especially in the epithelial layer. An increased expression of the transcription factor Sp1 was also demonstrated. The role of Sp1 in regulation of the genes affected in keratoconus was examined in this study.
METHODS: DNA segments, containing 5'-flanking promoter sequences of the alpha 1-PI, LAP, cathepsin B, and alpha 2-M genes were ligated into the secreted alkaline phosphatase (SEAP) reporter gene vector. These constructs, along with the pSV beta-galactosidase control vector, were transfected into cultured human corneal epithelial and stromal cells and skin fibroblasts. Cotransfection with the Sp1 expression vector was performed in parallel. SEAP and beta-galactosidase enzyme activities were assayed.
RESULTS: In corneal epithelial cells, as in stromal cells, alpha 1-PI promoter activity was suppressed by cotransfection of pPacSp1. The LAP, cathepsin B, and alpha 2-M promoters were functional in corneal cells, whereas activities of these promoters were much lower in skin fibroblasts. Cotransfection experiments indicated that the up- or downregulation of LAP, cathepsin B, and alpha 2-M observed in keratoconus-affected corneas was not mediated by Sp1.
CONCLUSIONS: These results support the theory that the corneal epithelium, along with the stroma, is involved in keratoconus. An upstream role of Sp1 is indicated and the Sp1-mediated downregulation of the alpha 1-PI gene may be a key event in the disease development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481261

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Histopathological and immunohistochemical studies of lenticules after epikeratoplasty for keratoconus.

Authors:  H Nakamura; F Riley; H Sakai; W Rademaker; B Y J T Yue; D P Edward
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  Effects of Sp1 overexpression on cultured human corneal stromal cells.

Authors:  Xiang Shen; Jeong-Seok Park; Ye Qiu; Joel Sugar; Beatrice Y J T Yue
Journal:  Genes Cells       Date:  2009-09-16       Impact factor: 1.891

3.  Ocular surface development and gene expression.

Authors:  Shivalingappa K Swamynathan
Journal:  J Ophthalmol       Date:  2013-02-21       Impact factor: 1.909

4.  A genome-wide association study of corneal astigmatism: The CREAM Consortium.

Authors:  Rupal L Shah; Qing Li; Wanting Zhao; Milly S Tedja; J Willem L Tideman; Anthony P Khawaja; Qiao Fan; Seyhan Yazar; Katie M Williams; Virginie J M Verhoeven; Jing Xie; Ya Xing Wang; Moritz Hess; Stefan Nickels; Karl J Lackner; Olavi Pärssinen; Juho Wedenoja; Ginevra Biino; Maria Pina Concas; André Uitterlinden; Fernando Rivadeneira; Vincent W V Jaddoe; Pirro G Hysi; Xueling Sim; Nicholas Tan; Yih-Chung Tham; Sonoko Sensaki; Albert Hofman; Johannes R Vingerling; Jost B Jonas; Paul Mitchell; Christopher J Hammond; René Höhn; Paul N Baird; Tien-Yin Wong; Chinfsg-Yu Cheng; Yik Ying Teo; David A Mackey; Cathy Williams; Seang-Mei Saw; Caroline C W Klaver; Jeremy A Guggenheim; Joan E Bailey-Wilson
Journal:  Mol Vis       Date:  2018-02-05       Impact factor: 2.367

Review 5.  The Proteins of Keratoconus: a Literature Review Exploring Their Contribution to the Pathophysiology of the Disease.

Authors:  Eleftherios Loukovitis; Nikolaos Kozeis; Zisis Gatzioufas; Athina Kozei; Eleni Tsotridou; Maria Stoila; Spyros Koronis; Konstantinos Sfakianakis; Paris Tranos; Miltiadis Balidis; Zacharias Zachariadis; Dimitrios G Mikropoulos; George Anogeianakis; Andreas Katsanos; Anastasios G Konstas
Journal:  Adv Ther       Date:  2019-07-30       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.